• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    H

    Hospital México

    ccss.sa.cr
    885论文总数
    1.6万引用总数

    Hospital México is a hospital located in the western part of San José in Costa Rica. The hospital, operated by the Costa Rican Social Security Fund, has 633 beds and it is certified for trauma and emergency medical services.

    论文量&引用量时间轴

    机构学者

    论文(886)

    年份
    起
    –
    止
    排序
    1Suzetrigine (a NaV1.8 Inhibitor) Versus Placebo for Acute Postoperative Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Pablo Alvarez-Aguilar, Susimar Picado-Loaiza

    BACKGROUND:NaV1.8 channels, expressed in peripheral nociceptors, mediate sustained pain signaling. Their inhibition offers a potential opioid-sparing strategy for postoperative pain, although efficacy and safety remain incompletely defined. We synthesized randomized evidence for suzetrigine versus placebo in postoperative pain. METHODS:We conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant meta-analysis of randomized controlled trials comparing suzetrigine (a NaV1.8 inhibitor) versus placebo in surgical patients. The primary outcome was 24-hour pain with the Numeric Pain Rating Scale; secondary outcomes included 48-hour pain, change-from-baseline, and adverse events. Risk of bias was assessed with the Cochrane Risk of Bias 2 tool, and for analyses, we used Hartung-Knapp models with heterogeneity and prediction intervals reported. Random-effects models used Hartung-Knapp adjustments (2-sided α = 0.05). RESULTS:We included 4 randomized datasets across 2 phase 3 publications (n = 1584; 1009 intervention, 575 placebo). The mean participant age was 44.9 years; 92.3% were women. Procedures included abdominoplasty (n = 823) and bunionectomy (n = 761). Suzetrigine significantly reduced pain at 24 hours (mean difference = -0.93; 95% confidence interval [CI], -1.38 to -0.48; I2 = 66.0%) and 48 hours (mean difference = -1.02; 95% CI, -1.32 to -0.72; I2 = 11.8%). Analyses of change-from-baseline confirmed consistent benefit. Subgroup analyses revealed similar effects across surgery types. A lower incidence of nausea (risk ratio = 0.63; 95% CI, 0.42-0.95) and dizziness (risk ratio = 0.57; 95% CI, 0.34-0.96) was observed in the suzetrigine group, with no significant differences in headache, vomiting, or constipation. Meta-regressions showed no moderation by sample size or publication year. Risk of bias was low in 2 studies and raised "some concerns" in 2. CONCLUSION:Suzetrigine produced modest reductions in pain at 24 to 48 hours versus placebo. Because opioid consumption was not consistently reported, no conclusions can be drawn regarding opioid-sparing.

    2026Medicine(2026)引用:2
    引用
    AI阅读
    加入学术空间
    2The Landscape of Dementia Research, Diagnosis, Treatment, and Care in Latin America.
    Claudia K Suemoto,Nilton Custodio, Diego Aguilar, José A Avila-Funes,Sandra Baez, Pablo M Bagnati,Lisa L Barnes,Sonia M D Brucki, Ismael L Calandri,Paulo Caramelli,Mario Cornejo-Olivas, Carolina Delgado Derio,

    Latin America is undergoing rapid population aging alongside a rising burden of dementia. While the region holds substantial potential for dementia risk reduction, challenges remain, such as delayed diagnoses, limited access to specialized care and biomarker testing, persistent stigma, and deep-rooted structural inequities. To address these gaps and foster regionally informed solutions, the Alzheimer's Association convened the 2025 Alzheimer's Association International Conference (AAIC) Satellite Symposium in Lima, Peru, on May 14-15, in collaboration with the Global Brain Health Institute (GBHI) and the Atlantic Fellows for Equity in Brain Health. The meeting aimed to bring core elements of the global AAIC meeting to regional Latin American settings, recognizing that national and cultural contexts demand tailored approaches to dementia prevention, risk reduction, treatment and care all aimed at promoting brain health in the region. This manuscript synthesizes the symposium's key discussions, scientific advances, and opportunities for collaboration across the region.

    2026Alzheimer's & dementia the journal of the Alzheimer's Association(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Real-World Outcomes of First-Line Pertuzumab, Trastuzumab, and Taxane in HER2-Positive Metastatic Breast Cancer in Costa Rica: A Multicenter Retrospective Study.
    Khanna Priyanka, Denis U Landaverde

    Background Dual HER2 blockade with pertuzumab, trastuzumab, and a taxane is the current standard first-line treatment for HER2-positive metastatic breast cancer (mBC), based on pivotal trials such as the CLEOPATRA. Since 2014, this regimen has been implemented in the Costa Rican public healthcare system. However, real-world data from Central America are lacking. Methods We conducted a retrospective, multicenter observational study of 148 patients with histologically confirmed HER2-positive mBC who were treated between August 2015 and August 2021 at five Costa Rican public hospitals. Primary endpoints were progression-free survival (PFS), overall survival (OS), and safety profile. Survival analysis was performed using Kaplan-Meier estimates. Results Median age was 58 years; 95% had ECOG 0-1; 54% were hormone receptor-positive. Visceral metastases were present in 37.8%, and 4.7% had brain metastases at diagnosis. Paclitaxel was the most used taxane (85%). Median duration of anti-HER2 therapy was 22.7 months. Median PFS was 19 months (95% CI: 15-25), and median OS was 73 months (95% CI: 38-74), with a median follow-up of 27.5 months. Most adverse events were grade 1-2, with peripheral sensory neuropathy (34%) and diarrhea (21%) being the most common. Grade 3 cardiotoxicity occurred in two patients. Subgroup analysis by hormone receptor status showed no statistically significant differences in PFS (HR-positive: 18.2 months (95% CI 14.1-22.3) vs. HR-negative: 20.1 months (95% CI 15.8-24.4); p = 0.42) or OS (HR-positive: 71 months (95% CI 36-106) vs. HR-negative: 74 months (95% CI 40-108); p = 0.38). Conclusion This first Central American real-world study demonstrates that first-line pertuzumab, trastuzumab, and taxane yields PFS, OS, and safety outcomes comparable to pivotal trials in HER2-positive mBC, despite including patients with prior trastuzumab exposure and brain metastases. These findings contribute to regional real-world evidence and underscore the need for neurological monitoring, given the high rate of central nervous system (CNS) progression. Cross-study comparisons remain descriptive due to population and design differences.

    2026Cureus(2026)
    引用
    AI阅读
    加入学术空间
    4Abstract PS5-10-21: Real-world Patterns and Preferences in the Use of Diagnostic Imaging for Breast Cancer Staging in Hispano-America: A Multinational Physician Survey
    W. A. Mantilla, M. A. Bravo, V. Acosta-Marín, A. M. Osorio, C. Villarreal-Garza, A. W. Mushtaq, F. E. Petracci, S. Cervera, G. Santander, A. Reyes-Morales, D. U. Landaverde, J. C. Samamé-Pérez-Vargas,

    Accurate staging of breast cancer (BC) is essential for guiding treatment decisions and estimating prognosis. Current guidelines discourage routine diagnostic imaging in asymptomatic patients. However, adherence is often inconsistent in clinical practice. In Latin America (LATAM), this is further challenged by higher rates of advanced-stage presentations and aggressive tumor subtypes, which may lead to more frequent imaging. Yet, there is a lack of data on real-world imaging patterns in the region. Understanding current staging practices is critical to identifying care gaps, informing context-appropriate guidelines, and promoting efficient diagnostic strategies. We conducted a cross-sectional, anonymous online survey among oncologists and breast surgeons from LATAM countries. The survey included 63 items covering sociodemographic characteristics, imaging use by clinical stage, decision-making criteria, access to diagnostic technologies, turnaround times, and familiarity with guidelines. Descriptive statistics were used for analysis. A total of 269 physicians participated. Respondents included physicians from 18 LATAM countries and Spain; 55.4% were oncologists and 44.6% breast surgeons; 57.3% worked primarily in public settings, and 55.4% had over 10 years of experience. While 43.5% managed more than 50 BC patients per month, only 18.2% were exclusively dedicated to BC care. Guideline awareness was high (NCCN: 89%, ESMO: 71.4%, national: 70.6%), and 89.1% stated that guideline recommendations were important for decision making in clinical practice. Despite this, routine use of diagnostic imaging was reported in 34.2% of asymptomatic patients with stage I disease, 48% in stage II without nodal involvement, 77.7% in stage II with nodal involvement, and 91.1% in stage III. Chest CT (65.9%), abdominal CT (63.2%), and bone scintigraphy (62.7%) were reported as the most frequently used studies, though abdominal ultrasound (US) (42.2%), chest X-ray (40.9%), and PET-CT (23.3%) were also reported. Imaging decisions were primarily influenced by tumor size (78.3%) and biological subtype (65.9%). Chest X-ray and abdominal US reported use decreased from 62.8% in stage I to 24.7% in stage III patients, while thoraco-abdominal CT use increased from 36.2% in stage I to 85.7% in stage III patients. The reported use of imaging did not change based on medical specialty or years of clinical practice. Access to advanced imaging modalities such as PET-CT was more restricted; only 43.9% had consistent availability, and 44.6% reported turnaround times >4 weeks, compared to <3% for chest X-ray or abdominal US, 15.9% for thoraco-abdominal CT, and 27.1% for bone scintigraphy. Most respondents (62.5%) indicated that imaging decisions and turnaround times (82.2%) would differ based on patients' insurance status (public vs private). Overall, the findings highlight a disconnect between guideline-based recommendations and real-world practice, shaped by system-level disparities and resource constraints. Our findings underscore a significant gap between guideline recommendations and real-world diagnostic imaging practices for BC staging across LATAM. Despite high awareness of guidelines, the frequent use of imaging reflects inconsistent adherence to guideline recommendations. Early-stage patients often undergo extensive imaging, with limited access and long delays—particularly for advanced modalities like PET-CT— that may contribute to treatment delays. These findings support the need for regionally adapted staging guidelines and targeted educational strategies to improve guideline-concordant care across LATAM. This work was conducted with the collaboration of LABCA, ACHO, ACM and SVM. W. A. Mantilla, M. A. Bravo, V. Acosta-Marín, A. M. Osorio, C. Villarreal-Garza, A. W. Mushtaq, F. E. Petracci, S. Cervera, G. Santander, A. Reyes-Morales, D. U. Landaverde, J. C. Samamé-Pérez-Vargas, J. Moreno-Rios, L. Gutiérrez, B. Moreno-Jaime, J. J. Caicedo, S. Quintero, A. M. Mejía, H. Carranza, S. X. Franco. Real-world patterns and preferences in the use of diagnostic imaging for breast cancer staging in Hispano-America: A multinational physician survey [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS5-10-21.

    2026Clinical Cancer Research(2026)
    引用
    AI阅读
    加入学术空间
    5Pulmonary Fungal Infections in Immunocompetent Patients.
    Juan José Arenas-Jiménez, Tomás Franquet, Randall Rojas-Varela, Irene Arco-Montoro, David Ferrández-Ferrández

    Fungi are a group of microorganisms encompassing thousands of species, with only a minority causing disease in humans. Fungal pathogens and infections are increasing global public health problems. They are an important cause of opportunistic infections in immunocompromised patients; however, they can also affect immunocompetent individuals. This paper reviews the incidence, clinical features, radiographic manifestations, and pathological findings of major fungal infections in non-immunocompromised patients. Only a restricted subset of fungi, specifically the endemic dimorphic fungi, selected Aspergillus manifestations, and Cryptococcus gattii are consistently associated with pulmonary infection in immunocompetent individuals. Endemic mycoses are determined by their geographic distribution, which makes it necessary to consider the diagnosis when pulmonary infection occurs in endemic areas. However, their clinical and radiological manifestations are frequently nonspecific. On the other hand, other fungi, mainly Aspergillusspp. are involved in a variety of diseases, including allergic bronchopulmonary aspergillosis, which is frequently diagnosed based on imaging criteria, and a series of conditions in the spectrum of chronic aspergillosis, including simple aspergilloma, chronic cavitary pulmonary aspergillosis, chronic fibrosing pulmonary aspergillosis, subacute invasive pulmonary aspergillosis, and aspergillus nodules.

    2026Journal of thoracic imaging(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 886 篇论文

    合作机构(100)

    墨西哥社会保障研究所合作论文 31
    哥斯达黎加大学合作论文 29
    丹佛卫生医疗中心合作论文 20
    Hospital San Juan de Dios合作论文 15
    墨西哥国立自治大学合作论文 13
    Universidad Nacional de Asunción合作论文 11
    大学医院(新泽西州纽瓦克)合作论文 10
    Hospital Italiano de Buenos Aires合作论文 10
    康奈尔大学合作论文 9
    Hospital General de México,Secretaria de Salud合作论文 9

    机构统计